ABC:NYE-AmerisourceBergen (USD)

COMMON STOCK | Medical Distribution | NYE

Last Closing Price

USD 170.29

Change

+0.97 (+0.57)%

Market Cap

USD 34.67B

Volume

1.22M

Avg Analyst Target

USD 173.00 (+1.59%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ABC Stock Forecast & Price:
Based on the AmerisourceBergen stock forecasts from 8 analysts, the average analyst target price for AmerisourceBergen is USD 173.00 over the next 12 months. AmerisourceBergen’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AmerisourceBergen is Slightly Bullish , which is based on 11 positive signals and 6 negative signals. At the last closing, AmerisourceBergen’s stock price was USD 170.29. AmerisourceBergen’s stock price has changed by -0.23% over the past week, +5.11% over the past month and +42.48% over the last year.

About AmerisourceBergen (ABC:NYE)

AmerisourceBergen Corporation sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute car ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-07 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MCK McKesson Corporation

+7.47 (+1.98%)

USD54.23B 27.03 14.77
CAH Cardinal Health Inc

+0.75 (+0.94%)

USD20.81B 35.81 -115.46
OMI Owens & Minor Inc

+0.70 (+3.44%)

USD1.55B 12.65 9.90
7459 Medipal Holdings Corp

N/A

N/A N/A N/A

ETFs Containing ABC

Symbol Name Weight Mer Price(Change) Market Cap
CHEP AGFiQ U.S. Market Neutral.. 0.00 % 1.42 %

N/A

USD0.75M
ESGF Invesco Global ESG Revenu.. 0.00 % 0.45 %

N/A

USD0.02B
FHC:CA First Trust Dow Jones Int.. 0.00 % 0.77 %

N/A

USD4.88M
FLAG First Light Acquisition G.. 0.00 % 1.44 %

N/A

USD0.10B
WBIF WBI BullBear Value 3000 E.. 0.00 % 1.39 %

+0.06 (+0.19%)

USD0.04B
WBIG WBI BullBear Yield 3000 E.. 0.00 % 1.33 %

+0.18 (+0.72%)

USD0.07B
FHC-F:CA First Trust Dow Jones Int.. 0.00 % 0.15 %

N/A

USD5.68M
GBLO Global Beta Low Beta ETF 0.00 % 0.29 %

N/A

USD5.83M

Market Performance

  Market Performance vs.
Industry/Classification (Medical Distribution)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 28.14% 50% F 94% A
Dividend Return 1.77% 67% D+ 37% F
Total Return 29.91% 50% F 94% A
Trailing 12 Months  
Capital Gain 40.91% 50% F 96% A
Dividend Return 1.94% 75% C 37% F
Total Return 42.85% 50% F 96% A
Trailing 5 Years  
Capital Gain 96.41% 75% C 90% A-
Dividend Return 10.35% 75% C 43% F
Total Return 106.76% 75% C 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 13.88% 50% F 79% C+
Dividend Return 1.80% 75% C 44% F
Total Return 15.68% 50% F 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 15.58% 100% A+ 69% D+
Risk Adjusted Return 100.65% 100% A+ 98% A+
Market Capitalization 34.67B 75% C 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Distribution)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.18 75% C 43% F
Price/Book Ratio 5.58 50% F 13% F
Price / Cash Flow Ratio 29.48 25% F 11% F
EV/EBITDA 12.01 50% F 32% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 29.17% 100% A+ 92% A-
Return on Assets 3.06% 50% F 57% F
Debt to Equity Ratio 6,499.46% 25% F 1% F
Technical Ratios  
Dividend Yield 1.12% 75% C 15% F
Short Ratio 3.15 50% F 36% F
Short Percent 4.02% 75% C 46% F
Beta 0.55 100% A+ 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.